GMI-1687 is under clinical development by GlycoMimetics and currently in Phase I for Sickle Cell Disease With Vaso-Occlusive Crisis. According to GlobalData, Phase I drugs for Sickle Cell Disease With Vaso-Occlusive Crisis have a 95% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GMI-1687’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GMI-1687 overview

GMI-1687 is under development for the treatment of vaso-occlusive crisis associated with sickle cell disease and inflammatory diseases, acute myelocytic leukemia and multiple myeloma. The drug candidate acts by targeting E-selectin. It is administered through subcutaneous and intravenous route.
It was also under development for the treatment of thrombosis and solid tumors. 

GlycoMimetics overview

GlycoMimetics is a clinical-stage biotechnology company that discovers and develops small molecule drugs for the treatment of cancer and inflammatory diseases. The company’s lead pipeline product, uproleselan, is being developed for the treatment of relapsed/refractory acute myeloid leukemia (AML) in adults. GlycoMimetics designs galectin inhibitors for advancing treatment options for various diseases. The company designs and tests viral and bacterial entry inhibitors for dendritic cell receptors. The company uses proprietary glycobiology technology to develop treatments for diseases. It also offers clinical research programs. GlycoMimetics is headquartered in Rockville, Maryland, the US.

For a complete picture of GMI-1687’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.